1. Comparison of antigen-specific B cell responses reveals disparity in immunogenicity and memory B cell formation across COVID-19 vaccine platforms

hLife |从灭活苗到mRNA疫苗：不同技术路线如何塑造免疫记忆？

通信作者：华兆林，侯百东

引用：

Guo C, Chai X, Baerlike M, et al. Comparison of antigen-specific B cell responses reveals disparity in immunogenicity and memory B cell formation across COVID-19 vaccine platforms. hLife 2024; 2: 625–640.

2. Ferritin-NP-preS1 vaccine synergizes with siRNA for sustained seroconversion against chronic hepatitis B in mice

hLife | 朱明昭团队发现siRNA联合纳米疫苗可实现慢性乙型肝炎的长期功能性治愈！

通信作者：王文君、朱明昭

本研究基于团队前期自主研发的铁蛋白纳米颗粒-preS1（Ferritin-NP-preS1）治疗性疫苗，联合已报道的HBV特异性siRNA（AD-66810），开发了一种新的联合治疗方案，在小鼠慢乙肝模型中取得了显著的治疗效果。

Wang W, Zhou X, Guo T, et al. Ferritin-NP-preS1 vaccine synergizes with siRNA for sustained seroconversion against chronic hepatitis B in mice. hLife 2025; 3: 357–359.

3. Mucosal adenovirus vaccine Ad5-XBB.1.5 boosting elicits nasal IgA and transiently prevents JN.1 wave infection for less than 6 months in real-world settings

hLife |广州医科大学赵金存/王延群研究团队证实黏膜疫苗抵抗JN.1效力不足六个月

通信作者：王延群、田新贵、朱爱如、张璐、赵金存

Wang Y, Wei P, Zhang J, et al. Mucosal adenovirus vaccine Ad5-XBB.1.5 boosting elicits nasal IgA and transiently prevents JN.1 wave infection for less than 6 months in real-world settings. hLife 2025; 3: 433–447.

4. Cross-platform compatibility of a structure-guided chimeric MPXV immunogen delivered via circular RNA delivery

通信作者：高福

The mpox outbreak was declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO) on two separate occasions. Currently, the prevention and control of mpox face severe challenges, including sustained human-to-human transmission, increasing frequency and geographic distribution of mpox outbreaks, and ongoing viral adaptive evolution. To evaluate the cross-platform compatibility of the immunogen design strategy, this study applies a previously designed "four-in-one" immunogen, AMA-aB—comprising single-chain dimeric A35, M1, and truncated forms of A29 and B6—within a circRNA vaccine form. In this study, the AMA-aB immunogen, when delivered via a circRNA platform, elicits both potent cellular and humoral immune response and confers complete protection against lethal poxvirus challenge in mice. Take together, our findings highlights the cross-platform compatibility of the structure-guided “all-in-one” chimeric immunogen design strategy and emphasize the critical influences of delivery platform on shaping the magnitude and specificity of the antigen-specific immune responses.

Ding H, Wu J, Liu Z, et al. Cross-platform compatibility of a structure-guided chimeric mpox virus immunogen delivered via circular RNA delivery. hLife 2025; 3: 651–654.

5. Developing next-generation tuberculosis vaccines based on pathogen–host interactions: Towards a holistic perspective

hLife | 着眼整体视角：基于病原-宿主互作研发下一代结核病疫苗

通信作者：刘翠华

本文系统总结了结核病疫苗研发的困境和挑战，阐述了结核病致病过程中结核分枝杆菌与宿主相互作用的研究进展，并进一步探讨了基于病原-宿主相互作用的新一代高效、低毒、持久的结核病疫苗研发新策略。

Lei Z, Wang J, Liu CH. Developing next-generation tuberculosis vaccines based on pathogen–host interactions: Towards a holistic perspective. hLife 2025; 3: 164–171.

6. Rabies virus glycoprotein: Structure, function, and antivirals

hLife | 四川大学逯光文研究团队梳理狂犬病毒糖蛋白变构过程的结构特征，助力新药研发

通信作者：逯光文

狂犬病是一类重要的、由狂犬病毒引起的急性人兽共患传染病，一旦发病几乎100%致死。本综述聚焦狂犬病毒的关键毒力因子——糖蛋白，系统总结了糖蛋白构象变化的结构特征及现有中和抗体和防治药物的阻断机制，为抗病毒靶点选择和药物设计提供理论支撑。

You Y, Yang F, Lin S, et al. Rabies virus glycoprotein: Structure, function, and antivirals. hLife 2026; 4: 67–86.

7. Systemic profiling of immune responses in healthy adults vaccinated with an RBD-targeting COVID-19 mRNA vaccine

通信作者：赵慧、秦成峰

Zhou C, Sun M, Huang X, et al. Systemic profiling of immune responses in healthy adults vaccinated with an RBD-targeting COVID-19 mRNA vaccine. hLife 2025; 3: 415–432.

8. Rethinking BCG vaccine delivery for enhanced efficacy: Are two distinct routes of BCG administration better than one?

通信作者：Melissa Dalcina Chengalroyen

This article highlights the potential of enhancing BCG vaccine efficacy against tuberculosis through alternative administration routes. While intradermal BCG vaccination has long been the standard, its variable effectiveness against adult pulmonary TB suggests the need for new strategies. Recent studies indicate that oral BCG vaccination can significantly boost mucosal immunity, which is critical for protection against respiratory infections. Combining oral and intradermal routes may thus offer a dual advantage, eliciting both systemic and mucosal immune responses. Future research should focus on validating the safety and efficacy of this combined approach in clinical settings to improve TB prevention.

Moseki RM, Chengalroyen MD. Rethinking BCG vaccine delivery for enhanced efficacy: Are two distinct routes of BCG administration better than one? hLife 2025; 3: 61–63.

9. Addressing COVID-19 vaccination hesitancy through community engagement and integration with primary health care services in Wakiso district, Uganda

通信作者：David Musoke

Musoke D, Masengere P, Ssembuusi A, et al. Addressing COVID-19 vaccination hesitancy through community engagement and integration with primary health care services in Wakiso district, Uganda. hLife 2025; 3: 455–457.

10. Safety, immunogenicity, and preliminary efficacy of a randomized clinical trial of omicron XBB.1.5-containing bivalent mRNA vaccine

hLife | 新冠疫苗随机临床研究揭示XBB.1.5双价疫苗的优效免疫原性

通信作者：周太成，游顶云，韦嘉，张子杰

Yu X, Yang W, Li W, et al. Safety, immunogenicity, and preliminary efficacy of a randomized clinical trial of omicron XBB.1.5-containing bivalent mRNA vaccine. hLife 2024; 2: 113–125.